Collapse all
The Business Model Canvas reveals a shift from a chronic-maintenance revenue model to a high-value, acute-intervention model. Success depends on navigating strict regulatory environments and securing high-cost reimbursement for a low-frequency treatment cycle.
4 Pharmaceutical Suppliers Providers of synthetic, medical-grade psilocybin formulations to ensure dosage consistency and legal compliance. Veterans Affairs (VA) Strategic partners for patient referrals and potential government-funded pilot programs for treatment-resistant veterans. Regulatory Bodies (FDA/DEA) Essential for maintaining the legal licensure required to administer scheduled substances in a clinical setting. Private Equity Healthcare Groups Capital partners to fund the rapid scaling of physical clinic infrastructure across multiple regions. 3 Clinical Administration Executing the high-intensity, single-dose administration protocol including pre-session preparation and post-session integration. Patient Screening Rigorous vetting of patients to identify those with treatment-resistant depression who meet safety criteria for rapid-response therapy. Outcome Monitoring Tracking MADRS score reductions and long-term durability of effects to provide evidence for insurance reimbursement. 3 Specialized Clinical Staff Psychiatrists and trained facilitators capable of managing the psychological experience of high-dose psilocybin. Certified Treatment Facilities Physical clinics designed for safety, comfort, and the specific requirements of psychedelic-assisted therapy. Clinical Protocols Proprietary operational workflows based on phase 2 trial data for 25mg dosing and psychological support. 3 Rapid Symptom Reduction Significant reduction in depression scores as early as day 8, bypassing the weeks of latency typical of SSRIs. Treatment for Resistance A viable clinical alternative for patients who have failed multiple traditional antidepressant trials. Durable Remission Long-term antidepressant effects lasting up to 12 months from a minimal number of doses, reducing daily medication burden. 2 High-Touch Clinical Care Intensive, supportive relationships during the acute intervention phase to ensure patient safety and psychological integration. Long-term Outcome Tracking Periodic follow-ups to monitor the durability of the response and manage potential relapses. 3 Psychiatric Referrals Direct referral pipelines from general psychiatrists who cannot treat resistant cases with standard meds. VA Healthcare Network Integration into the Veterans Affairs system for targeted delivery to high-need veteran populations. Insurance Provider Networks Direct contracting with health insurers to establish the RRDI clinic as a covered specialized provider. 3 Treatment-Resistant Patients Individuals with moderate-to-severe MDD who have not responded to traditional SSRIs or SNRIs. Health Insurance Providers Payers interested in reducing the long-term cost of chronic depression management through a one-time high-impact cure. Veterans Affairs (VA) Governmental health entities seeking rapid interventions for complex PTSD and depression in veterans. 3 Specialized Labor High costs for dual-facilitator staffing required for the duration of the psychedelic experience. Facility Overhead Costs associated with maintaining medical-grade, secure, and therapeutic environments. Compliance and Legal Ongoing expenses for DEA licensing, regulatory audits, and medical malpractice insurance. 3 Per-Treatment Fee High-margin, single-episode pricing for the 'single-dose' intervention package. Insurance Reimbursement Fee-for-service payments from health insurers based on the clinical efficacy of the rapid-response model. Government Contracts Fixed-price or per-patient contracts with the VA for specialized mental health delivery. The shift from a chronic-maintenance to an acute-intervention model requires a new value proposition and revenue structure for insurance and PE groups. · Generated 2026-09-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated